Company news
Jazz Pharmaceuticals plc news in 2019
Jazz Pharmaceuticals plc's news releases, calls and decks from 2019, newest first.
Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
November 14, 2019
Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences
November 13, 2019
Jazz Pharmaceuticals Announces Third Quarter 2019 Financial Results
November 4, 2019
Jazz Pharmaceuticals to Report 2019 Third Quarter Financial Results on November 5, 2019
October 21, 2019
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of CAR-T Associated Neurotoxicity
October 9, 2019
Jazz Pharmaceuticals Announces Webcast for World Sleep Congress Investor Update
September 17, 2019
Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences
August 26, 2019
Jazz Pharmaceuticals Announces Acquisition of Cavion, Inc.
August 11, 2019
Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
August 5, 2019
Jazz Pharmaceuticals to Report 2019 Second Quarter Financial Results on August 6, 2019
July 22, 2019
Jazz Pharmaceuticals Acquires Pre-clinical Pan-RAF Inhibitor Program from Redx Pharma
July 9, 2019
Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update
June 24, 2019
Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi(TM) (solriamfetol)
June 16, 2019
Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019
April 22, 2019
Decks in 2019
- 37th Annual J.P. Morgan Healthcare Conference (January 2019)
Conference · 7 slides · Jan 8, 2019